Medicure Grants Stock Options to Key Personnel

On October 1, 2026, Medicure Inc., a pharmaceutical company operating in the U.S. market, announced the issuance of stock options to select directors, officers, employees, and consultants. The options allow the purchase of 150,000 common shares at $2.88 per share. These options will vest over three years, becoming fully exercisable within five years. This grant aligns with Medicure's existing stock option plan and awaits TSX Venture Exchange approval.

Medicure specializes in pharmaceuticals and healthcare products, notably AGGRASTAT® and ZYPITAMAG®, in the U.S. It operates through subsidiaries like Medicure Pharma Inc. and Marley Drug Inc., offering wide-ranging pharmacy services, including free home delivery, across all U.S. states, D.C., and Puerto Rico.